drugset / Trial / NCT06664801

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

NCT06664801

Phase 2 Completed 164 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it

Timeline

Start
2024-11-14
Primary completion
2025-11-20
Completion
2025-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic 0.7 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 90 mg Subcutaneous